Valuation: OnKure Therapeutics, Inc.

Market Cap 166M 146M 136M 125M 234M 16.03B 238M 1.61B 631M 7.88B 625M 611M 27.24B P/E 2026 *
-1.74x
P/E 2027 * -1.93x
Enterprise Value 166M 146M 136M 125M 234M 16.03B 238M 1.61B 631M 7.88B 625M 611M 27.24B EV / Sales 2026 *
444x
EV / Sales 2027 * 250x
Free-Float
89.53%
Yield 2026 *
-
Yield 2027 * -
1 day-2.37%
1 week-1.90%
Current month-9.65%
1 month-2.37%
3 months-14.17%
6 months+40.61%
Current year+42.07%
1 week 3.91
Extreme 3.91
4.38
1 month 3.91
Extreme 3.91
4.79
Current year 2.23
Extreme 2.23
5.38
1 year 1.91
Extreme 1.91
5.38
3 years 1.7
Extreme 1.7
20
5 years 1.7
Extreme 1.7
20
10 years 1.7
Extreme 1.7
20
Date Insider Type Main position Quantity % Market Cap.
6/22/26 Sell

Chief Financial Officer

-303 0.0008%
6/22/26 Sell

Chief Executive Officer

-86 0.0002%
6/4/26 Free

Director

7,650 0.0189%
Change 5-day change 1-year change 3-year change Capi.($)
-2.37%-1.90%+78.35% - 166M
+1.07%-3.49%-3.35%+10.44% 46.86B
+0.25%+1.65%+399.22%+634.87% 40.23B
-0.27%+4.45%+11.81%+65.64% 36.23B
+0.35%+0.87%+4.46%-10.16% 34.72B
+3.14%+1.02%+4.76%+40.92% 27.89B
-0.73%+11.84%+34.39%+134.36% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%-3.43%+9.03% 13.12B
-2.68%-2.49%-11.36%-33.61% 12.7B
Average -0.04%+0.56%+57.21%+106.44% 24.54B
Weighted average by Cap. +0.48%+0.91%+74.42%+136.27%

Financials

2026 *2027 *
Net sales 375K 329K 306K 281K 528K 36.11M 536K 3.64M 1.42M 17.75M 1.41M 1.38M 61.39M 667K 586K 545K 500K 939K 64.2M 953K 6.47M 2.53M 31.56M 2.5M 2.45M 109M
Net income -63.4M -55.68M -51.78M -47.52M -89.28M -6.11B -90.65M -615M -240M -3B -238M -233M -10.38B -68.57M -60.23M -56.01M -51.39M -96.57M -6.6B -98.06M -665M -260M -3.25B -257M -252M -11.22B
Net Debt - -
Logo OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a pipeline of tumor-agnostic candidates. It is developing OKI-219, a selective PI3KaH1047R inhibitor, as its lead program. It is engaged in targeting oncogenic PI3Ka and has multiple programs designed to enable targeting of this key oncogene. It is focused on delivering highly selective drug candidates that preserve wild-type PI3Ka while targeting the PI3Ka-mutated cancers, initially in advanced breast cancer. Its lead product candidate, OKI-219, is advancing in a phase I clinical trial. It also focuses on a development candidate targeting the most common PI3Ka mutations, such as H1047R, E545K, and E542K. Additionally, it is developing an allosteric inhibitor molecule.
Employees
45
Date Price Change Volume
26-07-24 US$4.120 -2.37% 186,005
26-07-23 US$4.220 -2.31% 53,944
26-07-22 US$4.320 +3.60% 170,710
26-07-21 US$4.170 +1.21% 144,221
26-07-20 US$4.120 -1.90% 73,790
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.120USD
Average target price
19.50USD
Spread / Average Target
+373.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OKUR Stock